^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis
Published date:
11/24/2021
Excerpt:
A total of 32 trials involving 958 patients were included. The ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment, and antibody-drug conjugate (ADC) (T-DM1) were 22% (95% CI 11-31), 23% (95% CI 20-65), 26% (95% CI 14-39), and 16% (95% CI -6-37), while that of ADC (DS-8201) was 60% (95% CI 35-85)....In particular, ADC (DS-8201), pyrotinib, and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC.
DOI:
10.1111/bcp.15155
